New ALS drug trial aims to slow disease progression
Disease control
Not yet recruiting
This study tests a new drug, PLL001, in 153 adults with ALS (Lou Gehrig's disease). The goal is to see if it is safe and can slow the disease or improve survival. Participants will receive either the drug or a placebo daily for up to 24 weeks, with an option to continue longer.
Phase: PHASE1, PHASE2 • Sponsor: PLL TX AUSTRALIA PTY LTD • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC